Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C88329
http://purl.obolibrary.org/obo/NCIT_C88329
|
|---|---|
| Preferred Name | Vistusertib |
| Definitions |
An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway. |
|---|---|
| prefLabel | Vistusertib
|
| label | Vistusertib
|
| PDQ_Closed_Trial_Search_ID | 662098
|
| code | C88329
|
| Has_Target | |
| prefixIRI | NCIT:C88329
|
| in_subset |
See more
See less
|
| Display_Name | Vistusertib
|
| Preferred_Name | Vistusertib
|
| FDA_UNII_Code | 0BSC3P4H5X
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Vistusertib
|
| CAS_Registry | 1009298-59-2
|
| NCI_Drug_Dictionary_ID | 662098
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 662098
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C2981846
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |